Pasotuxizumab

Drug Profile

Pasotuxizumab

Alternative Names: AMG-212; BAY-2010112; MT-112; PSMA BiTE Antibody

Latest Information Update: 28 Apr 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Micromet Inc
  • Developer Amgen; Bayer HealthCare Pharmaceuticals
  • Class Antineoplastics; Bispecific antibodies; Immunoglobulin Fv fragments; Monoclonal antibodies
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 04 Apr 2016 Pasotuxizumab is still in phase I trials for Prostate cancer (Hormone refractory, Late-stage disease) in Austria and Germany (SC)
  • 07 Oct 2015 Phase-I clinical trials in Prostate cancer (Hormone refractory, Late-stage disease) in Austria and Germany (IV)
  • 24 Apr 2012 Bayer and Amgen plan a phase I trial for Prostate cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top